久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3 fiercebiotech
    July 31, 2018
    A phase 3 trial of RedHill Biopharma’s Crohn’s disease asset has met its primary endpoint. The study linked antibiotic cocktail RHB-104 to a higher rate of remission than placebo after 26 weeks, although the difference between the two arms shrunk later in
PharmaSources Customer Service